Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 8, 2009, Pages 812-817

  Cavalheiro, Beatriz Godoi ^a,b,c   Junqueira, Consuelo Rodrigues ^a   Brandão, Lenine Garcia ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Brasileiro de Controle do Cancer   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CARCINOGENESIS; CERVICAL LYMPH NODE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); ENDOCRINOLOGY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; MEDICAL SCHOOL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; THYROID GLAND; THYROID MEDULLARY CARCINOMA; THYROID NODULE; TISSUE PRESERVATION;

ADOLESCENT; ADULT; AGED; CARCINOMA, MEDULLARY; CHILD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 68949130169     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.92     Document Type: Article

References (24)

1. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36(1):128-137.
2. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002;52(4):255-264.
3. Kraiem Z, Korem S. Matrix metalloproteinases and the thyroid. Thyroid. 2000;10 (12):1061-1069.
4. Murray GI. Matrix metalloproteinases: a multifunctional group of molecules. J Pathol. 2001;195(2):135-137.
5. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepień H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid. 2002;12(8):655-662.
6. Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer. 2006; 13(4):1173-1183.
7. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003;194(1):1-11.
8. Nakopoulou L, Tsirmpa I, Alexandrou P, et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat. 2003;77(2):145-155.
9. Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma: a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 1999; 73(3):372-382.
10. Cvejić D, Savin S, Paunovic I, Tatic S, Havelka M. Immunohistochemical localization of matrix metalloproteinase-2 (MMP-2) in medullary thyroid carcinoma. Arch Oncol. 2000;8:95-97.
11. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch. 2001;438(2):121-128.
12. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 1999;59(2):467-473.
13. Zedenius J, Sta° hle-Bäckdahl M, Enberg U, et al. Stromal fibroblasts adjacent to invasive thyroid tumors: expression of gelatinase A but not stromelysin 3 mRNA. World J Surg. 1996;20(1):101-106.
14. Tomita T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology. 1997; 31(2):150-156.
15. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol. 1992;23(12):1395-1401.
16. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O, Resnick MB. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr Med Assoc J. 2002;4(4): 247-251.
17. Hofmann A, Laue S, Rost AK, Scherbaum WA, Aust G. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid. 1998;8(3):203-214.
18. Cavalheiro BG, Junqueira CR, Brandão LG. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Thyroid. 2008;18(8): 865-871.
19. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22(6):562-567; discussion 567-568.
20. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf ). 1998;48(3):265-273.
21. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med. 2005;257(1):50-59.
22. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and comparison of staging systems. Cancer. 2000;88(5):1139-1148.
23. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg. 2003; 128(1):115-123.
24. Korem S, Resnick MB, Kraiem Z. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. J Clin Endocrinol Metab. 1999;84(9):3322-3327.